Edwards Lifesciences price target lowered to $85 from $95 at Stifel

Stifel analyst Rick Wise lowered the firm’s price target on Edwards Lifesciences (EW) to $85 from $95 and keeps a Buy rating on the shares. Shares have been pressured recently due to concerns about an important, upcoming dataset; specifically, Edwards’ upcoming Partner 3 seven-year low-risk data set for read-out on October 27 at the TCT 2025 medical meeting. After having had conversations with twelve physicians key to the TAVR community, the firm says the docs with which it consulted believe the upcoming low-risk TAVR data at TCT are expected to show that TAVR remains non-inferior with referral patterns unchanged, the firm noted.